Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: vestor who wrote (829)	11/11/1998 8:36:00 PM
From: Doug Bean	Read Replies (1) \| Respond to of 1837

Vestor: Well the loss is much smaller even with sales being basically flat. its appears that they are beginning to produce much higher margin new products. At htis pace they would be profitable either next quarter or at least the following one . if they get a couple of new approvals of even smaller type drugs they should make it over the hump. That would really set the stage for Cenestin. If it happened then,, the stock would absolutely soar. i don't know how the public will take the earnings news. It looked good to me ,, but it still wasn't making money. CRDoug